BioAdaptives, Inc. engages in marketing, investigating, and distributing natural plant and algal-based products that improve health and wellness for humans and animals. The company is headquartered in Las Vegas, Nevada and currently employs 1 full-time employees. The company went IPO on 2014-07-09. The Company’s core business is to investigate, market and distribute natural plant, fungi, and algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties. Its products in development include a weight management supplement in a human clinical trial, Zeranovia. Zeranovia is made of natural ingredients and uses proprietary methods of optimizing the availability of nutrients in foods and beverages. Xcellara regenerative stem cell activator is in production. Xcellara is its regenerative wellness solution, to enhance performance, accelerate recovery, and revitalize health. PawPa Regen is the canine treat stem cell activator. PawPa Regen supports anti-aging and wellness. Its other products include MyndMed and Wynovia. MyndMed is designed to optimize multiple neurotransmitter systems and neuroprotective pathways.
BDPT stock price ended at $0.02 on 金曜日, after rising 0.00%
On the latest trading day Feb 06, 2026, the stock price of BDPT rose by 0.00%, climbing from $0.02 to $0.02. Throughout the session, the stock experienced a volatility of 0.00%, with prices fluctuating between a daily low of $0.02 and a high of $0.02. Alongside this price increase, trading volume also rose by 13.9K shares, reflecting strong market interest that may signal continued bullish momentum in the near term. In total, 6.2K shares were traded, amounting to a market value of approximately $240.2K.